Medicines authorised with a summary of the risk management plan (sRMP)

In connection with the approval of a risk management plan for a medicinal product for human use, a summary of the risk management plan for the medicinal product is prepared and made publicly available in accordance with the pharmacovigilance legislation which came into force in July 2012.

The summary is prepared by the marketing authorisation holder and approved by the Danish Medicines Agency. On the EMA's website, you can find the summaries of risk management plans for medicinal products with an authorisation granted under the Centralised Procedure.

You can find the summaries of risk management plans by searching for the product name or the active substance.

You can also find a summary of risk management plan by clicking the first letter of the relevant product name below.

Since medicinal products sometimes change names there can be divergent names in the summary of the risk management plan and on this website.

The name on the website will always be the most recently approved name for the product.

The name in the summary of the risk management plan can be a previously approved name of the product or the name(s) of the active substance(s).

Product Name Pharmaceutical Form Strength Active Substance Approval Date
Azacitidine "Stada" pulver til injektionsvæske, suspension; 25 mg/ml AZACITIDIN 26/03/2020
Azacitidine "Zentiva" pulver til injektionsvæske, suspension; 25 mg/ml AZACITIDIN 12/02/2019
Aztarol depottabletter; 2 mg ROPINIROLHYDROCHLORID 08/04/2015
Aztarol depottabletter; 3 mg ROPINIROLHYDROCHLORID 08/04/2015
Aztarol depottabletter; 4 mg ROPINIROLHYDROCHLORID 08/04/2015
Aztarol depottabletter; 8 mg ROPINIROLHYDROCHLORID 08/04/2015
Azzalure pulver til injektionsvæske, opløsning; Clostridium botulinum, type A toxin 20/01/2015

Did you get answers to your questions?

Please tell us how we can improve our website? Please note that we do not answer questions asked via this feature.


...